Molecular Biomarkers for the Evaluation of Colorectal Cancer
Publication Date: February 6, 2017
Last Updated: March 27, 2023
Diagnosis
Colorectal carcinoma patients being considered for anti-EGFR therapy must receive RAS mutational testing. Mutational analysis should include KRAS and NRAS codons 12, 13 of exon 2; 59, 61 of exon 3; and 117 and 146 of exon 4 (“expanded” or “extended” RAS). ( R , C , B , H )
616
Title
Molecular Biomarkers for the Evaluation of Colorectal Cancer
Authoring Organizations
American Society for Clinical Pathology
American Society of Clinical Oncology
Association for Molecular Pathology
College of American Pathologists